Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 1
2005 3
2006 2
2008 2
2009 7
2010 6
2011 8
2013 3
2014 1
2015 3
2016 7
2017 7
2018 4
2019 4
2020 9
2021 9
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Review: Ewing Sarcoma Predisposition.
Gargallo P, Yáñez Y, Juan A, Segura V, Balaguer J, Torres B, Oltra S, Castel V, Cañete A. Gargallo P, et al. Among authors: castel v. Pathol Oncol Res. 2020 Oct;26(4):2057-2066. doi: 10.1007/s12253-019-00765-3. Epub 2019 Oct 26. Pathol Oncol Res. 2020. PMID: 31656020 Free article. Review.
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK; INRG Task Force. Cohn SL, et al. Among authors: castel v. J Clin Oncol. 2009 Jan 10;27(2):289-97. doi: 10.1200/JCO.2008.16.6785. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047291 Free PMC article.
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN. Ladenstein R, et al. Among authors: castel v. Lancet Oncol. 2018 Dec;19(12):1617-1629. doi: 10.1016/S1470-2045(18)30578-3. Epub 2018 Nov 12. Lancet Oncol. 2018. PMID: 30442501 Clinical Trial.
[Neuroblastoma].
Castel V, Cañete A, Noguera R, Navarro S, Oltra S; Grupo Español de Neuroblastoma (SEOP). Castel V, et al. Clin Transl Oncol. 2005 Apr;7(3):133-45. doi: 10.1007/BF02708748. Clin Transl Oncol. 2005. PMID: 15899223 Review. Spanish. No abstract available.
Metabolomic profiling in neuroblastoma.
Quintás G, Yáñez Y, Gargallo P, Juan Ribelles A, Cañete A, Castel V, Segura V. Quintás G, et al. Among authors: castel v. Pediatr Blood Cancer. 2020 Mar;67(3):e28113. doi: 10.1002/pbc.28113. Epub 2019 Dec 4. Pediatr Blood Cancer. 2020. PMID: 31802629
Advances in emerging drugs for the treatment of neuroblastoma.
Berlanga P, Cañete A, Castel V. Berlanga P, et al. Among authors: castel v. Expert Opin Emerg Drugs. 2017 Mar;22(1):63-75. doi: 10.1080/14728214.2017.1294159. Epub 2017 Feb 22. Expert Opin Emerg Drugs. 2017. PMID: 28253830 Review.
Emerging drugs for neuroblastoma.
Castel V, Segura V, Berlanga P. Castel V, et al. Expert Opin Emerg Drugs. 2013 Jun;18(2):155-71. doi: 10.1517/14728214.2013.796927. Epub 2013 May 22. Expert Opin Emerg Drugs. 2013. PMID: 23692586 Review.
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.
Garaventa A, Poetschger U, Valteau-Couanet D, Luksch R, Castel V, Elliott M, Ash S, Chan GCF, Laureys G, Beck-Popovic M, Vettenranta K, Balwierz W, Schroeder H, Owens C, Cesen M, Papadakis V, Trahair T, Schleiermacher G, Ambros P, Sorrentino S, Pearson ADJ, Ladenstein RL. Garaventa A, et al. Among authors: castel v. J Clin Oncol. 2021 Aug 10;39(23):2552-2563. doi: 10.1200/JCO.20.03144. Epub 2021 Jun 21. J Clin Oncol. 2021. PMID: 34152804 Clinical Trial.
76 results